PDI ( PDII) said GlaxoSmithKline ( GSK) won't renew its contract sales engagement for 2007.

The Saddle River, N.J., contract sales outfit said the Glaxo deal represents $65 million to $70 million in annual revenue and will expire as scheduled on Dec. 31, 2006. PDI's revenue for 2005 was $319 million.

"While we are disappointed with this decision, we are proud of the work we have done for GSK over the past three years and look forward to working with them again in the future," said CEO Michael Marquardt. "Our immediate priority is to develop other opportunities to redeploy our employees who comprise this sales team."

More from Stocks

Markets Look Confused After Latest Beating

Markets Look Confused After Latest Beating

General Electric Expulsion From Dow Symbolizes Unsettled Week in Markets

General Electric Expulsion From Dow Symbolizes Unsettled Week in Markets

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In